Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP1A2 | P05177 | 1/20 | 0.62 |
| ▸ | CTDSP1 | Q9GZU7 | 1/20 | 0.54 |
| ▸ | P2RX7 | Q99572 | 1/20 | 0.51 |
| ▸ | MAPT | P10636 | 1/20 | 0.50 |
| ▸ | TSHR | P16473 | 1/20 | 0.48 |
| ▸ | CA12 | O43570 | 1/20 | 0.46 |
| ▸ | CA1 | P00915 | 1/20 | 0.46 |
| ▸ | CA2 | P00918 | 1/20 | 0.46 |
| ▸ | CA7 | P43166 | 1/20 | 0.46 |
| ▸ | CA9 | Q16790 | 1/20 | 0.46 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.46 |
| ▸ | LMNA | P02545 | 1/20 | 0.46 |
| ▸ | FAAH | O00519 | 1/20 | 0.44 |
| ▸ | BRD4 | O60885 | 1/20 | 0.44 |
| ▸ | GAA | P10253 | 1/20 | 0.44 |
| ▸ | POLB | P06746 | 1/20 | 0.43 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.43 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.43 |
| ▸ | HPGD | P15428 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29427469 | 1.00 | CYP1A2 (0.62) | CYP1A2CTDSP1P2RX7MAPTTSHR | |
| SCHEMBL27748069 | 0.83 | L3MBTL1 (0.56) | CYP1A2P2RX7MAPTTSHRALDH1A1 | |
| SCHEMBL1403542 | 0.83 | P2RX7 (0.49) | CYP1A2CTDSP1P2RX7MAPTTSHR | |
| SCHEMBL20188582 | 0.81 | ALDH1A1 (0.53) | CYP1A2CTDSP1P2RX7MAPTTSHR | |
| SCHEMBL30817753 | 0.81 | ALDH1A1 (0.53) | CYP1A2CTDSP1P2RX7MAPTTSHR | |
| SCHEMBL5642066 | 0.81 | CYP1A2 (0.64) | CYP1A2MAPTTSHRCA12CA1 | |
| SCHEMBL16532538 | 0.80 | CTDSP1 (0.56) | CYP1A2CTDSP1P2RX7MAPTTSHR | |
| SCHEMBL11507652 | 0.80 | P2RX7 (0.50) | CYP1A2CTDSP1P2RX7MAPTALDH1A1 | |
| SCHEMBL6602091 | 0.79 | P2RX7 (0.56) | CYP1A2P2RX7MAPTTSHRCA12 | |
| SCHEMBL11528907 | 0.79 | CTDSP1 (0.48) | CYP1A2CTDSP1P2RX7MAPTTSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 37 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-117580835-A | MEK inhibitors and uses thereof | 医肯纳肿瘤学公司 | 2024-02-20 | — | — | CN | disclosed |
| CN-111918651-B | GCN2 inhibitors and uses thereof | 默克专利股份有限公司 | 2024-01-30 | — | — | CN | disclosed |
| CN-117043164-A | Imidazopyridazine or pyrazolopyrimidine compounds and compositions | 安锐生物医药科技(广州)有限公司 | 2023-11-10 | — | — | CN | disclosed |
| CN-116744929-A | Compounds and uses thereof | 福霍恩治疗公司 | 2023-09-12 | — | — | CN | disclosed |
| WO-2023155900-A1 | FIVE-MEMBERED AND SIX-MEMBERED HETEROCYCLIC COMPOUND, AND USE THEREOF AS PROTEIN KINASE INHIBITOR | 上海轶诺药业有限公司 | 2023-08-24 | — | — | WO | disclosed |
| CN-116547279-A | Heterocyclic GLP-1 agonists | 加舒布鲁姆生物公司 | 2023-08-04 | — | — | CN | disclosed |
| CN-116547278-A | Heterocyclic GLP-1 agonists | 加舒布鲁姆生物公司 | 2023-08-04 | — | — | CN | disclosed |
| CN-116507337-A | ATR inhibitors and uses thereof | 上海德琪医药科技有限公司 | 2023-07-28 | — | — | CN | disclosed |
| CN-116178391-A | Forward allosteric modulators of muscarinic acetylcholine receptor M4 | 范德比尔特大学 | 2023-05-30 | — | — | CN | disclosed |
| WO-2023083362-A1 | DRUG FOR TREATING TUMORS | 石药集团中奇制药技术（石家庄）有限公司 | 2023-05-19 | — | — | WO | disclosed |
| CN-105992768-B | The Imidazopyridazine compounds of conditioning agent as the response of IL 12, IL 23 and/or IFN α | 百时美施贵宝公司 | 2018-04-20 | — | — | CN | disclosed |
| CN-103596957-B | Imidazopyridazines as AKT kinase inhibitors | 拜耳知识产权有限责任公司 | 2016-12-07 | — | — | CN | disclosed |
| CN-105992768-A | Imidazopyridazine compounds useful as modulators of il-12, il-23 and/or ifn alpha responses | 百时美施贵宝公司 | 2016-10-05 | — | — | CN | disclosed |
| US-9394309-B2 | Substituted phenylimidazopyrazoles and their use | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2016-07-19 | — | — | US | disclosed |
| US-20150005288-A1 | SUBSTITUTED PHENYLIMIDAZOPYRAZOLES AND USE THEREOF | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2015-01-01 | — | — | US | disclosed |
| US-20130190290-A1 | Substituted phenylimidazopyrazoles and their use | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2013-07-25 | — | — | US | disclosed |
| US-8314240-B2 | Sulfonamide compounds or salts thereof | ASTELLAS PHARMA INC. (JP) | 2012-11-20 | — | — | US | disclosed |
| US-20110201616-A1 | SULFONAMIDE COMPOUNDS OR SALTS THEREOF | ASTELLAS PHARMA INC. (JP) | 2011-08-18 | — | — | US | disclosed |
| EP-2217601-A1 | IMIDAZOPYRIDAZINES FOR USE AS PROTEIN KINASE INHIBITORS | Centro Nacional de Investigaciones Oncológicas (CNIO) (ES) | 2010-08-18 | — | — | EP | disclosed |
| WO-2009060197-A1 | IMIDAZOPYRIDAZINES FOR USE AS PROTEIN KINASE INHIBITORS | CENTRO NACIONAL DE INVESTIGACIONES ONCOLOGICAS (CNIO) (ES) | 2009-05-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150005288-A1 | SUBSTITUTED PHENYLIMIDAZOPYRAZOLES AND USE THEREOF | VHL, FLT4, FLT1 | CYP1A2 1974/4885CTDSP1 2620/4885P2RX7 1959/4885 |
| US-20110201616-A1 | SULFONAMIDE COMPOUNDS OR SALTS THEREOF | PTGER1, PTGER2, GPER1 | CYP1A2 1777/4885CTDSP1 3210/4885P2RX7 164/4885 |
| US-20130190290-A1 | Substituted phenylimidazopyrazoles and their use | VHL, FLT4, FLT1 | CYP1A2 1927/4885CTDSP1 2298/4885P2RX7 1979/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.